Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Manufacturing Expert James Gizzi of Rochester Discusses How to Choose a CNC Machine Shop in HelloNation
-
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relaps
-
How Roofing Expert Tom Meadows of Ann Arbor Explains Roof Repair vs. Roof Replacement for HelloNation
-
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
-
New Crypto Mutuum Finance Completes Phase 1 Roadmap Milestones, Builds Momentum Into Phase 2
-
2025 "Silk Road for All Children" International Children's Literature Week The 10th Fairy Tales Conference Held in Wuyi, China
-
Funding Reaches $19.2M as Mutuum Finance (MUTM) Presale Moves Toward Full Allocation
-
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
-
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
-
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual M
-
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
-
Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
-
Remedy's Nutrition® Launches Cyst-Be-Gone™ — Advanced Herbal Formula to Support Natural Cyst & Tissue Wellness
-
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
-
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
-
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
-
BexBack Launches $100 Welcome Bonus and 100% Deposit Match as It Expands 100x Crypto Futures Trading Program
-
Roofing Expert Keith Miller Clarifies Why Flashing Is the Source of Many Roof Leaks in HelloNation
-
RadiantVibe Capital Consortium Debuts Insight Access Dashboard as Part of Ambrose Wetherby’s Transparency Initiative
-
Mutuum Finance Completes Lending and Borrowing Smart Contracts Ahead of Security Review
-
Anthony Constantino’s ‘Thank You President Trump’ Album Release To Light Up Fontainebleau LIV Tonight; Hit song “Fight” has over 4 million views in 5 days
-
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
-
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
-
JCBC Publishing, LLC Announces Launch of 'That Kind of Girl,' Jacey Bici's Debut Novel, in 2025
-
JCBC Publishing, LLC Announces Launch of 'That Kind of Girl,' Jacey Bici's Debut Novel, in 2025
-
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at
-
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematolog
-
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
-
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
-
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist
-
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meet
-
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compo
-
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
-
Canada’s Tenth Costco Business Centre is now open in East Gwillimbury
-
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
-
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
-
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Societ
-
BI DeFi Launches New Daily Yield Plan as Demand for Accessible Crypto Income Solutions Grows
-
DeFi Crypto Mutuum Finance Prepares for 20% Price Increase as Phase 6 Nears Completion
-
New Crypto Coin Mutuum Finance Nears 100% of Phase 6 Allocation as Price Shift Approaches
-
Scatec starts commercial operation at Grootfontein solar power plant in South Africa
-
Cardinal Point Wealth Management Releases New 2025 Cross-Border Retirement Guide for High-Net-Worth Families
-
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
-
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
-
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress
-
Copper Quest Closes $1,927,000 Private Placement
-
AB Value Partners, L.P. Announces Proposed Settlement of Stockholder Class Action on Behalf of Former Holders of Orbit/FR, Inc. Common Stock - ORFR
-
HNI Corporation Announces Expiration and Final Results of Exchange Offer
-
Guardian Capital Announces Estimated 2025 Annual Non-Cash Distributions for Guardian Capital ETFs
-
Webus International Limited Issues Clarification on Previous Announcement Related to Expedia Group

